Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
soft tissue sarcomas
Biotech
Shasqi snatches $50M for chemotherapy-boosting treatments
Shasqi has collected $50 million in a series B financing to fuel the path through the clinic.
Emmy Lucas
Nov 11, 2021 6:30am
ASCO: Adaptimmune’s cell therapy shrinks 39% of rare sarcomas
May 19, 2021 5:00pm
Epizyme's sarcoma drug sails through FDA panel
Dec 18, 2019 6:23pm
FDA raises doubts about benefits of Epizyme's cancer drug
Dec 17, 2019 8:10am
With FDA review nearing, Epizyme shares updated sarcoma data
Jun 3, 2019 9:15am
ESMO18: Tazemetostat update sets Epizyme up for first FDA filing
Oct 22, 2018 8:00am